HIV drug resistance over the long haul

Clinical Infectious Diseases

Volumn 50, Issue 9, 2010, Pages 1286-1287

  Harrigan, P Richard ^a  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

CLINICAL TRIAL; DRUG MONITORING; FOLLOW UP; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; NOTE; PRIORITY JOURNAL; UNITED KINGDOM;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS;

EID: 77951009588     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/651685     Document Type: Note

References (1)

1. The UK Collaborative Group on HIV Drug Resistance and UK CHIC Study Group. Longterm probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy. Clin Infect Dis 2010; 50(9): 1275-1285 (in this issue).